Levetiracetam Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 250 mg, 500 mg, 750 mg, 1000 mg
Reference Brands: US: Keppra®, Keppra XR®; EU: Keppra®, Levetiracetam Teva®, EpiKeppra®, Zentiva®
Category:
Antipsychotropic Drugs
Levetiracetam modulates synaptic neurotransmitter release by binding to SV2A, a protein involved in vesicle exocytosis, thereby stabilizing neural activity. It is prescribed for managing partial-onset, myoclonic, and generalized tonic-clonic seizures in both adults and children. The tablet form ensures convenient, consistent dosing for long-term seizure control.
Levetiracetam Tablets is available in Tablets
and strengths such as 250 mg, 500 mg, 750 mg, 1000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Levetiracetam Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Levetiracetam Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Levetiracetam Tablets are FDA-approved in the USA for the treatment of partial-onset, myoclonic, and generalized tonic-clonic seizures in adults and children from 4 years of age. They meet GMP standards and require labeling for neuropsychiatric effects, especially in pediatric use. In the European Union, Levetiracetam Tablets are approved under mutual recognition or decentralized procedures, depending on the manufacturer, and must include Risk Management Plans (RMPs) and regular safety reporting (PSURs). Generic versions must demonstrate bioequivalence. Levetiracetam remains a widely used antiepileptic across global markets. Explore reliable B2B suppliers at Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing